FDA Grants Accelerated Approval to Bosutinib for Treatment of Newly-Diagnosed PH+ CML
Dec 18
2017
The Food and Drug Administration granted accelerated approval to bosutinib (BOSULIF, Pfizer Inc.) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).
